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Abstract
Background: Guidelines for the control of hospital-acquired MRSA include decolonization measures to end MRSA
carrier status in colonized and infected patients. Successful decolonization typically requires up to 22 days of
treatment, which is longer than the average hospital length of stay (LOS). Incomplete decolonization is therefore
common, with long-term MRSA carriage as a consequence. To overcome this, we developed an integrated MRSA
Management (IMM) by extending MRSA decolonization to the outpatient and domestic setting. The protocol
makes use of polyhexanide-based products, in view of reported qac-mediated resistance to chlorhexidine in S.
aureus and MRSA.
Methods: This is a prospective, single centre, controlled, non-randomized, open-label study to evaluate the
efficiency of the IMM concept. The outcome of guideline-approved decolonization during hospital stay only
(control group; n = 201) was compared to the outcome following IMM treatment whereby decolonization was
continued after discharge in the domestic setting or in a long-term care facility (study group; n = 99). As a
secondary outcome, the effect of MRSA-status of skin alterations was assessed.
Results: The overall decolonization rate was 47 % in the IMM patient group compared to 12 % in the control
group (p < 0.01). The continued treatment after hospital discharge was as effective as treatment completed
during hospitalization, with microbiologically-confirmed decolonization (patients with completed regimes only)
obtained with 55 % for the IMM group and 43 % for the control group (p > 0.05). For patients with skin alterations (e.g.
wounds and entry sites), decolonization success was 50 % if the skin alterations were MRSA-negative at baseline,
compared to 22 % success for patients entering the study with MRSA-positive skin alterations (p < 0.01).
Conclusions: The IMM strategy offers an MRSA decolonization protocol that is feasible in the domestic setting and is
equally effective compared with inpatient decolonization treatment when hospital LOS is long enough to complete
the treatment. Moreover, for patients with average LOS, decolonization rates obtained with IMM are significantly higher
than for in-hospital treatment. IMM is a promising concept to improve decolonization rates of MRSA-carriers for
patients who leave the hospital before decolonization is completed.
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Background
Control and prevention of MRSA infections in a health-
care setting is an ongoing challenge that requires critical
infection control measures [1–3]. Various protocols have
emerged over the years to prevent nosocomial transmis-
sion, and national guidelines for the control of MRSA in
hospitals are now in place in many parts of the world
(e.g. [4–6], reviewed in [7]). As part of these guidelines,
decolonization of MRSA carriers is often recommended,
since this can effectively reduce the risk of infection, in
particular when performed prior to high-risk interven-
tions such as surgery or central catheter insertion [8].
Universal decolonization of all patients has been shown
to reduce bloodstream infections in an intensive care
setting even more effectively in comparison to targeted
decolonization of carriers only [9].
MRSA colonization is frequently persistent in adults, as
demonstrated by the fact that approximately half of the
patients tested positive upon admission were still positive
one year later [10]. The decolonization procedure nor-
mally takes approximately 7 days, but when unsuccessful
it needs to be repeated, and combined with the required
culture diagnostics, this adds up to 15 to 20 days for a
complete decolonization procedure. However, the average
length of hospital duration is typically shorter than this
and continues to decline over time; in 2009 the reported
average LOS for acute care varied from in 18.5 days in
Japan to 3.9 days in Mexico, with an average of 7.2 days
for all OECD countries [11]. In Germany, the average
LOS of 9.7 days in 2009 was decreased to 7.4 days in 2014
[12]. Clearly, short hospital stays hamper completion of
decolonization cycles. Typically, the microbiological
follow-up of inpatients is omitted so that the carrier status
of patients at discharge is uncertain.
Unfortunately, a significant proportion of MRSA-positive
admissions are readmissions; published data vary from
35 % [13] to 68 % [14]. In our experience approximately
half of all MRSA-positive inpatients are readmissions.
These patients have often been subjected to incomplete
decolonization treatment during a previous hospital stay,
in which case the procedure needs to be restarted upon re-
admission. For these patients, the risks related to MRSA
carriage persist despite having experienced the discom-
fort of decolonization attempts, while for the hospital
such ineffective decolonization efforts add to the
MRSA-associated economic burden [15, 16]. Moreover,
incomplete decolonization attempts can potentially se-
lect for resistant bacterial populations [17].
To overcome the limitations of MRSA decolonization
of inpatients with short hospitalization duration, we de-
veloped a new strategy for an Integrated MRSA Manage-
ment (IMM). An essential component of IMM is that
MRSA decolonization and concomitant diagnostics does
not terminate with discharge, but are continued in the
patient’s domestic setting until successful decolonization
has been demonstrated by microbiological culture.
The aim of the current prospective, single centre,
controlled, non-randomized, open-label study was two-
fold: it was performed to assess if the IMM strategy
was able to improve the overall success rate of MRSA
decolonization, and, in addition, to compare the ob-
tained results of IMM decolonization with success rates
of inpatient decolonization only. The effect of MRSA-
status of skin alterations was assessed as a secondary
outcome. In view of reported chlorhexidine resistance in S.
aureus as well as in MRSA due to acquired qac resistance
genes [18, 19], and based on past experience with inpatient
decolonization, we mostly applied polyhexanide-based
products for the decolonization procedures in the inpatient
control group as well as the IMM study group.
Methods
Study concept
A schematic of the study concept is shown in Fig. 1. The
study was performed in a tertiary care teaching hospital in
the Rhine-Main metropolitan area, Germany. Patients ad-
mitted to surgical as well as internal medicine units were
considered for inclusion, with the exception of admissions
to paediatrics and intensive care. For the inpatient control
group (represented to the right of Fig. 1b), patients were re-
cruited from 810 adults admitted to the study hospital be-
tween August 2007 and May 2009, who were positive with
MRSA as established by screening upon entry or during
diagnostic procedures, or with a known prior status (for
readmissions). Out of these, 201 patients with a hospital
stay of at least 7 days were chosen, which was the main in-
clusion criterion for the inpatient control group. Further,
these patients were at least 18 years of age and, although
identified as MRSA carriers, showed no symptoms of an
acute MRSA infection. This resulted in a Full Analysis Set
(FAS) of 201 patients for the inpatient control group, who
received all decolonization procedures routinely used in
the hospital, as described in the Additional file 1. Briefly,
the nasal cavity was decolonized with mupirocin 3 times
daily for 5 days, after which Prontoderm was used twice
daily. All other body parts were treated on a daily basis
with the Polyhexanide-based products listed in Table 1 (all
products by B. Braun Medical AG, Sempach, Switzerland).
Patient’s utensils and environment were disinfected or
cleaned according to the hospital’s routine regime. The sta-
tus of colonization was assessed every 7 days and the
decolonization regime was terminated when an MRSA-free
status was achieved (see below). Decolonization procedures
were also terminated in case of discharge, irrespective of
their MRSA status.
The criterion for The IMM group was that decolonization
treatment was completely or partly performed in the out-
patient setting (Fig. 1b). Patients were recruited for the
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IMM cohort during the same period as above, from either
admissions (n = 62), or actively contacted based on their
MRSA status that was known from previous admissions.
The latter were recruited either from long-term care facil-
ities (LTCF) (n = 12) or from domestic settings (n = 25);
these patients received the complete treatment at LTCF or
at home, performed by a nurse under supervision of hos-
pital staff. This resulted in a FAS of the IMM group of 99
patients. The treatment regime was identical between in-
patient control group and IMM group, other than the loca-
tion of the IMM patients during (part of) their treatment.
The total study thus comprised 300 investigated pa-
tients, 182 male and 118 female, whose pre-existing skin
alterations (e.g. wounds or catheter entry sites) were re-
corded by the visiting study nurse, for which personnel
was appointed; this personnel was supervised by the
overseeing infection control nurse.
According to national guidelines, MRSA decolonization
procedures were regarded as successful when 3 consecutive
sets of negative MRSA samples were obtained from a pa-
tient. The PPS of the inpatient control group comprised of
those patients who were successfully decolonized, as well
as patients who had completed the full decolonization
procedure covering 22 ± 3 days, but who at the end pro-
duced fewer than 3 subsequent sets of negative MRSA-
control samples obtained. This was scored as unsuccessful
decolonization. In the IMM intervention group, six pa-
tients prematurely discontinued the study and nine
additional patients were excluded due to schedule inter-
ruptions, thus resulting in a PPS of the intervention
group of 84 patients who completed the decolonization
procedure and follow-up, with the outcome of success-
ful or unsuccessful decolonization, as defined above.
All procedures were documented on site by handheld-
based data acquisition.
Determining MRSA status and decolonization procedures
MRSA colonization status was determined by a series of
swab samples taken from the nares, oral cavity/throat, ears/
hairline and abdomen/groin as standard localizations (repre-
senting one sample series) and from representative skin al-
terations if applicable (e.g. wounds and catheter entry sites).
The sampling regime is summarized in the Additional file 1.
Microbiological culture was performed according to stand-
ard procedures. Briefly, cotton swabs with transport Amies
media (Sarstedt, Germany) were moistened with sterile
Table 1 Polyhexanide-based antiseptics used for decolonization
Decolonization site Polyhexanide concentration Other ingredients
ProntOral® throat, mouth wash 0.15 % Aroma, sodium cyclamate, surfactants, excipients
Prontoderm® Nasal gel nose 0.1 % Glycerine, hydroxyethylcellulose, excipients
Prontosan® Solution wound irrigation 0.1 % Betaine surfactant
Prontoderm® Solution/Foam whole-body/hair washing, external
auditory canal (Solution only)
0.11 % Surfactants, excipients
A B
Fig. 1 Schematic of the study. In panel (a), the procedure is shown, with arrows representing actions and boxes representing an MRSA status.
The asterisks indicate that the decolonization treatment could be repeated with a maximum of 3 treatments in total. Depending on the number
of required decolonization treatments (1 to 3) the procedure was completed in 11 to 25 days. Panel (b) shows the inpatient control group and
the IMM group. The treatment regime was the same for both, though the location of the patients differed
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normal saline (B. Braun, Germany) prior to sampling. Each
swab was transferred to 10 ml TSB broth culture (bioMér-
ieux, Germany) and microbial growth was visually assessed
by turbidity after 24 h and 48 h incubation. Samples without
detectable growth after 48 h were considered negative. For
those samples showing bacterial growth, cultures were
plated on selective chromogenic media (Oxoid Brilliant
MRSA Agar, Oxoid, Germany) for 18 - 24 h.
For initial MRSA-diagnostic, colonies morphologically
corresponding to presumptive MRSA on chromogenic
media were further validated by biochemical characterisa-
tion (Vitek 2, bioMérieux, Germany), presence of PBP2a
(Slidex MRSA-detection, bioMérieux) and antibiotic testing
(Vitek 2, bioMérieux). When morphology on chromogenic
substrate and the biochemical tests were in accordance,
subsequent samples of the same patient were considered
MRSA-positive, corresponding with growth on the select-
ive, chromogenic media.
The decolonization treatment was terminated in case
the patient’s status changed to MRSA negative. All recom-
mended elements of inpatient MRSA decolonization ac-
cording to the national (German) guidelines [6] were
adapted for the IMM group to be performed in the out-
patient setting by home care nursing. Samples for MRSA
screening were taken at the day of admission and, when
all requirements were met, the patient was enrolled at day
1, receiving decolonization treatment. When all samples
from a sample series were negative, treatment was stopped
and sampling was immediately repeated (Fig. 1). Individ-
ual patients received a maximum of three decolonization
treatments, giving a complete duration of 25 days at most.
The primary efficacy variable was the rate of successful
MRSA-decolonization in the IMM-study population com-
pared to the control group.
All antiseptics used for decolonization contained poly-
hexanide (polyaminopropyl biguanide), as the active com-
ponent, with the exception of mupirocin used for nasal
treatment during the first 5 days. Standard hygiene mea-
sures, including wound care procedures were applied to
all patients enrolled upon demand. All decolonization and
wound care procedures were performed in accordance
to national recommendations, accompanied by a daily
decontamination/disinfection of items involved in pa-
tient’s personal hygiene, surfaces in the patient’s prox-
imity, a daily change of bed linen, as well as a change
of body clothes following each body washing. A chart
of the practical procedures is available as supplemen-
tary information.
Statistical analysis
The primary efficacy variable was compared using a Chi-
Square test with error probability α = 0.05. Continuous
and categorical variables are described by: number of
valid cases, mean, median, standard deviation, minimum,
maximum, and number of valid cases, frequency and
percentage, respectively. All statistical analyses were per-
formed using SAS® Version 9.1.3.
Results
Study population
The age and gender distribution of the study population
is shown in Table 2; demographics did not differ signifi-
cantly between IMM and control group. The FAS of the
intervention group for the IMM study cohort com-
prised 99 MRSA-positive patients. After exclusion of 15
patients, for reasons described in the Methods, 84 pa-
tients were valid for the PPS (Table 2). A quarter of
these patients had been admitted from home. Of the 62
patients who were recruited during hospitalization, 55
received MRSA decolonization treatment prior to dis-
charge, varying from 2 to 21 days of duration. Twelve







(N = 99) (N = 201)
Age years years
Mean 68 71
Standard deviation ±15 ±13
Range 27-96 20-95
Age category N (%) N (%)
<65 years 35 (35 %) 56 (28 %)
>65 years 64 (65 %) 145 (72 %)
Gender N (%) N (%)
Male 60 (61 %) 122 (61 %)
Female 39 (39 %) 79 (39 %)
Skin alterations N (%) N (%)
With skin alterations 60 (61 %) 136 (68 %)
Without skin alterations 39 (39 %) 65 (32 %)
B. Study entry description
Patients with entry
in the study from
N (%) N (%)
Hospital 62 (63 %) Hospital inpatient,
by default
Long-term care 12 (12 %)
Patient’s home 25 (25 %)
Discharge location (IMM only)
Hospital 0 not applicable
Long-term care 22 (22 %)
Patient’s home 77 (78 %)
Patients not completing 6 (6 %) 0
Protocol violations 9 (9 %) 0
Per protocol Set (PPS) N = 84 N = 54b
at-test (age): p > 0.05. Chi-square test (gender, skin alterations): p > 0.05
bPPS inpatient control group: LOS of 22 ± 3 decolonization days or three
negative MRSA-swabs
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patients who were enrolled lived in long-term care fa-
cilities. The decolonization treatment was continued
after discharge as required, which took place in the pa-
tient’s home in 77 cases and in long-term care in 22
cases (Table 2).
The FAS of the inpatient control group represented
201 patients (total control group). These patients re-
ceived decolonization treatment only during their
hospitalization stay. Of these patients, 54 were valid for
the PPS (control group with completed decolonization
cycle and follow-up in the hospital).
Overall decolonization results
Considering the complete patient groups (FAS), at the end
of the study 46 patients of the intervention IMM group
(47 %) had become MRSA-free, while 53 (53 %) had
remained MRSA-positive. Of these, one patient produced
two negative swabs only, resulting in an indecisive status
which we screened as positive. In the control group 24 in-
patients had become MRSA-free (12 %) while 177 remained
positive (88 %) of which 59 were indecisive. The difference
in decolonization performance between the two groups was
statistically significant (p < 0.001). Table 3A summarizes the
Table 3 Obtained MRSA-status at the end of the study, FAS and PPS results
A. Full Analysis Set (FAS) of 300 subjects
Final MRSA-status n (%) Interventional IMM-population Inpatient control group Chi-square test for final
MRSA-status











N = 39 N = 60 N = 99 N = 65 N = 136 N = 201
MRSA-free (3 neg. swabs series) 27 19 46 8 16 24 For all patients: p < 0.001
(69 %) (32 %) (47 %) (12 %) (12 %) (12 %)
Two negative swabs series 0 1 1 8 11 19 For patients without skin
alterations: p < 0.001
(2 %) (1 %) (12 %) (8 %) (9 %)
One negative swab series 0 0 0 15 25 40
(23 %) (18 %) (20 %)
Remainder MRSA-positive 12 40 52 34 84 118 For patients with skin
alterations: p < 0.001
(31 %) (67 %) (52 %) (53 %) (62 %) (59 %)
Total MRSA-positve 12 41 53 57 120 177
(31 %) (69 %) (53 %) (88 %) (88 %) (88 %)
Chi-square test for final MRSA-status Patients with and without
skin alterations: p < 0.001
Patients with and without
skin alterations: p > 0.05
B. Per Protocol Set (PPS) of 138 subjects with completed decolonization + follow-up
Final MRSA-status n (%) Interventional IMM-population Inpatient control group Chi-square test for final
MRSA-status











N = 36 N = 48 N = 84 N = 14 N = 40 N = 54
MRSA-free (3 neg. swabs series) 27 19 46 7 16 23 For all patients: p > 0.5
(75 %) (40 %) (55 %) (50 %) (40 %) (43 %)
Two negative swabs series 0 0 0 5 6 11 For patients without
skin alterations: p > 0.5
(36 %) (15 %) (20 %)
One negative swab series 0 0 0 0 7 7
(18 %) (13 %)
Remainder MRSA-positive 9 29 38 2 11 13 For patients with skin
alterations: p > 0.5
(25 %) (60 %) (45 %) (14 %) (27 %) (24 %)
Total MRSA-positve 9 29 38 7 24 31
(25 %) (60 %) (45 %) (50 %) (60 %) (57 %)
Chi-square test for final MRSA-status Patients with and without
skin alterations: p < 0.01
Patients with and without
skin alterations: p > 0.05
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data for the FAS populations. A significant difference was
also observed when the comparison was restricted to pa-
tients with skin alterations: 32 % turned MRSA-negative in
the intervention IMM group compared to 12 % in the con-
trol group, or to patients without skin alterations (69 % for
the intervention IMM group compared to 12 % for control
group, in both cases p < 0.001).
Table 3B summarizes the results for the PPS, when the
analysis was restricted to patient populations with com-
pleted decolonization protocols and a microbiological
follow-up, either in the IMM study group or the inpatient
control group. This analysis resulted in similar success
rates for both groups (intervention group 46/84 or 55 %;
inpatient control group: 23/54 or 43 %, p > 0.05), indicating
that continuation of IMM treatment after discharge can be
as effective as when performed within the hospital. A com-
parison within the IMM population between patients with
and without skin alterations resulted in a significantly bet-
ter decolonization rate for the latter (p < 0.01), whereby pa-
tients without skin alterations represented the minority in
both populations (36/84 or 43 % in the IMM-population
and 14/54 or 26 % in the control group).
Patient demography, hospitalization, and body-site specific
data
Patient’s gender did not affect decolonization outcome,
but as shown in Fig. 2 (panel a), with increasing age
decolonization success decreased, both in the IMM and
in the control group. The difference was significant for
the control group only when comparing patients youn-
ger than 60 years to those over 74 years (p < 0.05).
The inhospital control group was used to assess the ef-
fect of LOS duration. This varied from 10 days to 28 days,
with a mean of 16.1 days in the enrolled patients. Although
longer LOS resulted in a higher percentage of decolonized
patients, the result was not significant. Figure 2b shows the
analysis for three cohorts with different LOS; a division for
hospitalization shorter or longer than 14 days resulted in
12 % MRSA-free patients in both groups.
The inhospital control group comprised 99 patients who
were readmissions. Of these, 12 turned MRSA-negative
during the study (12 %), compared to 12 of 101 patients
(12 %) who had not been hospitalized in the year previous
to admission (p > 0.05) (Fig. 2c). Whether decolonization
attempts had been performed during previous admissions
Fig. 2 Analysis of patient demography, hospitalization and body-site specific data. The percentage of patients turned MRSA-negative is shown in
grey, absolute numbers are shown below the column, e.g., 14 turned negative out of 26 patients. Significance is indicated as *p < 0.05,
**p < 0.01 and ***p < 0.001
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was not recorded, but prior hospitalization did not affect
the outcome of decolonization.
We further analysed whether the length of the
decolonization procedure correlated with the outcome.
The mean duration of decolonization was 13.6 days for
the complete inpatient group and 10.7 days for the control
group. Decolonization treatment was successful after
7.5 days on average for IMM patients and 7.4 days on
average in the control group. Decolonization success de-
creased with its duration; Panel d of Fig. 2 shows the
breakup into three groups. While 25 of 27 patients in the
IMM turned negative after 9 days or less of decolonization,
only 7 of 44 did so after treatment longer than 14 days
(this difference was statistically significant, p < 0.001). For
the inpatient control group, 16 of 73 patients turned nega-
tive within 9 days, but only 2 after longer than 14 days of
treatment (p < 0.01). Prolonged decolonization (>14 days)
resulted in 7 and 2 patients with an MRSA-free status in
the IMM and control group, respectively.
Analysis of the data with respect of the site of
colonization (irrespective of presence of skin alterations,
which is discussed below) revealed that there was no sig-
nificant difference between IMM and control group for
site-specific positive results obtained at baseline. As ex-
pected, MRSA was most frequently detected in the nares
(45 % in the IMM group compared to 44 % in controls),
followed by the abdomen/groin (33 % and 32 %, respect-
ively), hairline/ears (27 % for each group) and oral cavity/
throat (27 % for the IMM and 29 % for the control group).
The overall difference in decolonization performance be-
tween IMM and inpatient control group was also observed
when site-specific colonization at baseline was analyzed.
The only significant finding when analysing baseline data
per body site was that control patients negative at hairline/
ears at baseline were more frequently completely negative
at the end of the study, which was found for 13 out of 66
patients (20 %, p < 0.05).
Patients who were proven positive at more than one
body site at baseline were also separately analysed. For the
IMM group, there was no difference in decolonization
performance for these patients compared to cases with
one site-specific MRSA-positive sample at baseline, while
in the inpatient control group none of the 33 cases posi-
tive at 2 or more body sites had turned completely nega-
tive at the end of the study, compared to 24 cases turning
to a negative status with fewer than 2 positive body sites
at baseline (p < 0.05).
Decolonization rates related to MRSA in skin alterations
The secondary outcome of the study focused on the 138
patients who had finished the complete decolonization
protocol irrespective of their location (in the hospital,
N = 54 or after discharge, N = 84) to analyse the effect
of skin alterations that had been present at baseline. Of
89 patients with skin alterations at the beginning of the
procedure, 34 (38 %) had become MRSA-negative after
completion of decolonization, while 33 of the 49 pa-
tients without skin alterations (67 %) had become nega-
tive (p = 0.001) (Fig. 3a). When present at the beginning
of the study, the MRSA-status of such skin alterations
was recorded. A success rate of 50 % was observed in
patients with MRSA-negative skin alterations at the start
of intervention (24 of 48), compared to a decolonization
rate of 22 % in patients testing positive for MRSA in skin
alterations (9 of 41) (p < 0.01) (Fig. 3b).
Discussion
MRSA decolonization guidelines define a multimodal ap-
proach to abolish MRSA carriage. The impact of each
component of the typical treatment is not fully understood.
It has been reported that stay at ICU was the most strongly
associated with decolonization success, while of the clas-
sical decolonization steps with nasal mupirocin treatment,
chlorhexidine body wash and povidone-iodine wound
treatment, the latter was most strongly correlated to suc-
cess [20]. In another study, whole body wash with 4 %
chlorhexidine solution for 5 days resulted in an eradication
rate of 8 % only, while more extensive treatment was re-
quired for complete eradication of MRSA colonization
[21]. An earlier study reported an 18 % eradication rate by
chlorhexidine washing which was improved to 25 % when
used in combination with mupirocin [22]. Various regimes
using mupirocin for nasal decolonization, combined with
A B
Fig. 3 Effect of skin alterations on success rate of decolonization. Panel
(a) shows the effect of absence or presence of skin alterations for PPS
patients (intervention group and inpatient control group combined)
upon admission. Panel (b) shows the effect of the MRSA-status of the
skin alterations at baseline. (Significance **p < 0.01 and ***p < 0.001)
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octenidine, quaternary ammonium compounds or phenox-
yethanol have also been reported to be effective against
MRSA colonization [23–25].
Due to developed antibiotic resistance, alternatives to
chlorhexidine are needed, for which data on efficacy are
highly needed [26, 27]. Relatively few studies exist to date
regarding MRSA-decolonization with polyhexanide, a
product that is recommended for treating critically colo-
nized, infected and chronic wounds [28]. It can be used in
combination with antibiotic treatment or on its own and is
equally effective against MRSA and methicillin-susceptible
S. aureus [29]. Moreover, polyhexanide has been suggested
as an alternative agent for decolonization of mupirocin-
resistant (mupA-carrying) or chlorhexidine-resistant (qac-
carrying) strains [30]. Disappointing results, namely 33.8 %
decolonization, were obtained when polyhexanide was ap-
plied in a double-blind placebo-controlled trial in a teach-
ing hospital [31]. In that study, treatment was performed
for 7 days only, while successful decolonization was de-
fined by negative samples at the end of treatment. We be-
lieve that a single polyhexanide-based decolonization
course can be insufficient for MRSA-positive patients, and
our results support this view. In addition, although the
placebo-group in the study by Landelle and co-workers
used the product without polyhexanide, another ingredient
in the placebo formulation was shown to have an unex-
pected anti-staphylococcal activity [32], hence possibly re-
ducing the difference observed between treatment and
placebo group. That study also included decolonization
treatment in outpatient settings, for which even fewer
studies exist. Here, the impact of insufficient compliance
on decolonization rate remained an open question [31].
In our study, the rate of over 50 % successful MRSA-
decolonization seen in the PPS groups for both the in-
patient as well as the IMM population indicates that a
polyhexanide-based MRSA-decolonization treatment
also provides a suitable approach to eradicate MRSA. In
accordance to our results, the long-term care patients
studied by Wendt and co-workers resulted in a similar
outcome of decolonization success compared to the hos-
pital inpatient group [21].
The presence of skin alterations has been recognized as
a risk factor for decolonization failure [20, 24], though this
notion was contradicted by others [25]. Our data confirm
that the presence of wounds and skin entries can hamper
decolonization, although the effect is relatively minor for
skin alterations that are free of MRSA: a success rate of
75 % MRSA eradication in IMM patients without skin al-
teration was reduced to 50 % when skin alterations were
negative for MRSA. The success rate was lower when the
skin alterations were MRSA-positive at base line (18 %).
These results underline the importance of wound care in
MRSA management, as recently discussed by Meyer and
co-workers [33]. A pilot study evaluating polyhexanide-
mediated eradication of MRSA in chronic leg ulcers re-
ported that eradication of MRSA in chronic wounds in
outpatients is indeed possible [34].
There are several limitations to our study. Since this
work was performed in and supervised from a single hos-
pital, external validity of the results is not available. Al-
though we believe that the IMM protocol can be easily
adapted to other hospitals, generalization of the study re-
sults depends on practicalities and local habits that may
affect the outcome. Moreover, patients were not followed-
up to assess the long-term effects of decolonization. In
addition, although readmissions were recorded, any previ-
ous decolonization attempts performed in other hospitals,
the used products and their outcomes were not available
for analysis. Further, data on body-site specific colonisation
status at baseline were not always complete, so that ana-
lysis of the effects of these must be interpreted with care.
Finally, transient colonization may have influenced our
outcome. Transient colonization has been described for
patients in LTCF as well as health care workers (e.g., [35]),
but to our knowledge no data are available for a compari-
son between LTCF and in-house patients. Therfore, we do
not know whether or to what degree transient colonization
would affect the inpatient and control groups.
Our work builds on these data and shows that con-
tinuing the decolonization regime after hospital dis-
charge can increase the success rate. The IMM strategy
presented here offers an MRSA-decolonization protocol
that is equally effective in an outpatient setting as is
long-term inpatient decolonization treatment. In par-
ticular, the IMM strategy is recommended for short LOS
patients. This study is the first to compare a combin-
ation of in- and outpatient MRSA-decolonization in-
cluding treatment in a domestic setting, with a control
group of patients undergoing decolonization whose dur-
ation is limited to the hospital stay.
Conclusions
The work reported here provides proof of concept for a
new and effective MRSA decolonization strategy, whereby
decolonization can successfully be continued after hospital
discharge. The study highlights the decolonization proced-
ure as a pivotal treatment, which should be independent
of the medical institution and solely dependent on the
colonization status of the patient.
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